Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.4 GBX | -1.45% | -10.53% | -20.00% |
May. 23 | Celadon ships to US; Oxford BioDynamics-Goodbody pact | AN |
May. 23 | Fusion Antibodies plc Announces New Contract with Existing Client Project to Develop Therapeutic | CI |
Sales 2024 * | 1.14M 1.46M | Sales 2025 * | - | Capitalization | 3.24M 4.15M |
---|---|---|---|---|---|
Net income 2024 * | -1M -1.28M | Net income 2025 * | - | EV / Sales 2024 * | 2.84 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.1
x | P/E ratio 2025 * |
-
| Employees | 48 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.63% |
1 day | -1.45% | ||
1 week | -10.53% | ||
Current month | -9.33% | ||
1 month | +1.49% | ||
3 months | -12.82% | ||
6 months | -30.26% | ||
Current year | -20.00% |
Managers | Title | Age | Since |
---|---|---|---|
Adrian Kinkaid
CEO | Chief Executive Officer | 57 | 22-08-14 |
Stephen Smyth
DFI | Director of Finance/CFO | 49 | 23-08-23 |
Simon Douglas
CHM | Chairman | 65 | 05-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Colin Walsh
BRD | Director/Board Member | 68 | 06-12-31 |
Simon Douglas
CHM | Chairman | 65 | 05-12-31 |
Richard Buick
CTO | Chief Tech/Sci/R&D Officer | 47 | 01-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-06 | 3.4 | -1.45% | 233,441 |
24-06-05 | 3.45 | 0.00% | 440,789 |
24-06-04 | 3.45 | -1.43% | 631,093 |
24-06-03 | 3.5 | -6.67% | 920,828 |
24-05-31 | 3.75 | -1.32% | 474,407 |
Delayed Quote London S.E., June 06, 2024 at 11:35 am EDT
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-20.00% | 4.2M | |
+55.55% | 59.34B | |
+43.17% | 40.24B | |
-4.71% | 39.88B | |
-5.56% | 28.55B | |
+13.76% | 27.26B | |
-22.00% | 19.23B | |
+31.50% | 12.61B | |
+2.16% | 12.49B | |
+25.70% | 12.28B |
- Stock Market
- Equities
- FAB Stock